Autism, mitochondria and polybrominated diphenyl ether exposure

CNS and Neurological Disorders - Drug Targets

Volumn 15, Issue 5, 2016, Pages 614-623

  Wong, Sarah ^a   Giulivi, Cecilia ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antioxidant response; Autism risk; Mitochondrial dysfunction; Neuronal development; Oxidative stress; PBDE exposure

Indexed keywords

2,2',4,4' TETRABROMODIPHENYL ETHER; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYBROMINATED DIPHENYL ETHER; POLYCHLORINATED BIPHENYL; PROTEIN KINASE C; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NRF2; DIPHENYL ETHER DERIVATIVE;

ANTIOXIDANT ACTIVITY; ARTICLE; AUTISM; BROMINATION; CELL PROLIFERATION; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENVIRONMENTAL EXPOSURE; GENE EXPRESSION; IMMUNE DYSREGULATION; MITOCHONDRIAL DYNAMICS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PERIPHERAL BLOOD MONONUCLEAR CELL; TRANSCRIPTION REGULATION; AUTISM SPECTRUM DISORDER; AUTISTIC DISORDER; CHILD; CHILD DEVELOPMENT; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MITOCHONDRIAL DISEASES; MITOCHONDRION; PHYSIOLOGY;

AUTISM SPECTRUM DISORDER; AUTISTIC DISORDER; CHILD; CHILD DEVELOPMENT; ENVIRONMENTAL EXPOSURE; FEMALE; HALOGENATED DIPHENYL ETHERS; HUMANS; MALE; MITOCHONDRIA; MITOCHONDRIAL DISEASES;

EID: 84974678215     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527315666160413122624     Document Type: Article

References (226)

1. Hallmayer J, Cleveland S, Torres A, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry 2011; 68(11): 1095-102.
2. Zota AR, Rudel RA, Morello-Frosch RA, Brody JG. Elevated house dust and serum concentrations of PBDEs in California: unintended consequences of furniture flammability standards? Environ Sci Technol 2008; 42(21): 8158-64.
3. Dingemans MM, van den Berg M, Westerink RH. Neurotoxicity of Brominated Flame Retardants: (In-)Direct Effects of Parent and Hydroxylated Polybrominated Diphenyl Ethers on the (Developing) Nervous System. Environ Health Perspect 2011; 119(7): 900-7.
4. Coburn CG, Curras-Collazo MC, Kodavanti PRS. In vitro effects of environmentally relevant polybrominated diphenyl ether (PBDE) congeners on calcium buffering mechanisms in rat brain. Neurochem Res 2008; 33(2): 355-64.
5. Dingemans MML, Heusinkveld HJ, Bergman A, van den Berg M, Westerink RHS. Bromination Pattern of Hydroxylated Metabolites of BDE-47 Affects Their Potency to Release Calcium from Intracellular Stores in PC12 Cells. Environ Health Perspect 2010; 118(4): 519-25.
6. Hu X, Hu D, Xu Y. Effects of tetrabrominated diphenyl ether and hexabromocyclododecanes in single and complex exposure to hepatoma HepG2 cells. Environ Toxicol Pharmacol 2009; 27(3): 327-37.
7. Huang SC, Giordano G, Costa LG. Comparative cytotoxicity and intracellular accumulation of five polybrominated diphenyl ether congeners in mouse cerebellar granule neurons. Toxicol Sci 2010; 114(1): 124-32.
8. Kodavanti PRS. Differential effects of polybrominated diphenyl ethers and polychlorinated biphenyls on intracellular signaling in rat neuronal cultures. Organohalogen Compd 2003; 65: 1-4.
9. Dingemans MML, de Groot A, van Kleef RG, et al. Hydroxylation increases the neurotoxic potential of BDE-47 to affect exocytosis and calcium homeostasis in PC12 cells. Environ Health Perspect 2008; 116(5): 637-43.
10. Shao J, White CC, Dabrowski MJ, Kavanagh TJ, Eckert ML, Gallagher EP. The role of mitochondrial and oxidative injury in BDE 47 toxicity to human fetal liver hematopoietic stem cells. Toxicol Sci 2008; 101(1): 81-90.
11. Yu K, He Y, Yeung LWY, Lam PKS, Wu RSS, Zhou B. DE-71-induced apoptosis involving intracellular calcium and the Baxmitochondria-caspase protease pathway in human neuroblastoma cells in vitro. Toxicol Sci 2008; 104(2): 341-51.
12. He P, Wang AG, Xia T, et al. Mechanisms underlying the developmental neurotoxic effect of PBDE-47 and the enhanced toxicity associated with its combination with PCB153 in rats. Neurotoxicology 2009; 30: 1088-95.
13. Yan C, Huang D, Zhang Y. The involvement of ROS overproduction and mitochondrial dysfunction in PBDE-47-induced apoptosis on Jurkat cells. Exp Toxicol Pathol 2011; 63: 413-7.
14. Dingemans MML, van den Berg M, Bergman A, Westerink RHS. Calcium-related processes involved in the inhibition of depolarization-evoked calcium increase by hydroxylated PBDEs in PC12 cells. Toxicol Sci 2010; 114(2): 302-9.
15. Kodavanti PRS, Ward TR. Differential effects of commercial polybrominated diphenyl ether and polychlorinated biphenyl mixtures on intracellular signaling in rat brain in vitro. Toxicol Sci 2005; 85(2): 952-62.
16. Reistad T, Fonnum F, Mariussen E. Neurotoxicity of the pentabrominated diphenyl ether mixture, DE-71: and hexabromocyclododecane (HBCD) in rat cerebellar granule cells in vitro. Arch Toxicol 2006; 80(11): 785-96.
17. Lunder S, Hovander L, Athanassiadis I, Bergman O. Significantly Higher Polybrominated Diphenyl Ether Levels in Young U.S. Children than in Their Mothers. Environ Sci Technol 2010; 44(13): 5256-62.
18. Branchi I, Capone F, Alleva E, Costa LG. Polybrominated diphenyl ethers: Neurobehavioral effects following developmental exposure. Neurotoxicology 2003; 24(3): 449-62.
19. Schecter A, Johnson-Welch S, Tung KC, Harris TR, Papke O, Rosen R. Polybrominated diphenyl ether (PBDE) levels in livers of U.S. human fetuses and newborns. J Toxicol Environ Health A 2007; 70(1): 1-6.
20. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry 2012; 17(3): 290-314.
21. Chauhan A, Gu F, Essa MM, et al. Brain region-specific deficit in mitochondrial electron transport chain complexes in children with autism. J Neurochem 2011; 117(2): 209-20.
22. Haas RH. Autism and mitochondrial disease. Dev Disabil Res Rev 2010; 16(2): 144-53.
23. Giulivi C, Zhang YF, Omanska-Klusek A, et al. Mitochondrial dysfunction in autism. JAMA 2010; 304: 2389-96.
24. Oliveira G, Diogo L, Grazina M, et al. Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Dev Med Child Neurol 2005; 47(3): 185-9.
25. Arnoult D, Soares F, Tattoli I, Girardin SE. Mitochondria in innate immunity. EMBO Rep 2011; 12(9): 901-10.
26. Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun 2012; 26(3): 383-92.
27. Napoli E, Hung C, Wong S, Giulivi C. Toxicity of the flameretardant BDE-49 on brain mitochondria and neuronal progenitor striatal cells enhanced by a PTEN-deficient background. Toxicol Sci 2013; 132(1): 196-210.
28. Giulivi C, Napoli E, Schwartzer J, Careaga M, Ashwood P. Gestational exposure to a viral mimetic poly(i:C) results in longlasting changes in mitochondrial function by leucocytes in the adult offspring. Mediators Inflamm 2013; 2013: 609602.
29. Bernier FP, Boneh A, Dennett X, Chow CW, Cleary MA, Thorburn DR. Diagnostic criteria for respiratory chain disorders in adults and children. Neurology 2002; 59(9): 1406-11.
30. Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry 2012; 71(11): 956-61.
31. Frye R. Biomarker of abnormal energy metabolism in children with autism spectrum disorder. N Am J Med Sci Monit 2012; 5: 141-7.
32. Napoli E, Wong S, Giulivi C. Evidence of reactive oxygen speciesmediated damage to mitochondrial DNA in children with typical autism. Mol Autism 2013; 4(1): 2.
33. Lee HC, Yin PH, Chi CW, Wei YH. Increase in mitochondrial mass in human fibroblasts under oxidative stress and during replicative cell senescence. J Biomed Sci 2002; 9(6 Pt 1): 517-26.
34. Liu CS, Tsai CS, Kuo CL, et al. Oxidative stress-related alteration of the copy number of mitochondrial DNA in human leukocytes. Free Radic Res 2003; 37(12): 1307-17.
35. Tang G, Gutierrez Rios P, Kuo SH, et al. Mitochondrial abnormalities in temporal lobe of autistic brain. Neurobiol Dis 2013; 54: 349-61.
36. DeVito TJ, Drost DJ, Neufeld RW, et al. Evidence for cortical dysfunction in autism: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 2007; 61(4): 465-73.
37. Amaral DG, Schumann CM, Nordahl CW. Neuroanatomy of autism. Trends Neurosci 2008; 31(3): 137-45.
38. Graf WD, Marin-Garcia J, Gao HG, et al. Autism associated with the mitochondrial DNA G8363A transfer RNA(Lys) mutation. J Child Neurol 2000; 15(6): 357-61.
39. Goh S, Dong Z, Zhang Y, DiMauro S, Peterson BS. Mitochondrial dysfunction as a neurobiological subtype of autism spectrum disorder: evidence from brain imaging. JAMA Psychiatry 2014; 71(6): 665-71.
40. Frye RE, Rossignol DA. Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders. Pediatr Res 2011; 69(5 Pt 2): 41R-7R.
41. Scaglia F, Towbin JA, Craigen WJ, et al. Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics 2004; 114(4): 925-31.
42. Hagerman R, Hoem G, Hagerman P. Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Mol Autism 2010; 1(1): 12.
43. Zingerevich C, Greiss-Hess L, Lemons-Chitwood K, et al. Motor abilities of children diagnosed with fragile X syndrome with and without autism. J Intellect Disabil Res 2009; 53(1): 11-8.
44. Harris SW, Hessl D, Goodlin-Jones B, et al. Autism profiles of males with fragile X syndrome. Am J Ment Retard 2008; 113(6): 427-38.
45. Napoli E, Ross-Inta C, Wong S, et al. Mitochondrial dysfunction in Pten haplo-insufficient mice with social deficits and repetitive behavior: interplay between Pten and p53. PLoS One 2012; 7(8): e42504.
46. Grosser E, Hirt U, Janc OA, et al. Oxidative burden and mitochondrial dysfunction in a mouse model of Rett syndrome. Neurobiol Dis 2012; 48(1): 102-14.
47. Gibson JH, Slobedman B, Kn H, et al. Downstream targets of methyl CpG binding protein 2 and their abnormal expression in the frontal cortex of the human Rett syndrome brain. BMC Neurosci 2010; 11: 53.
48. Condie J, Goldstein J, Wainwright MS. Acquired microcephaly, regression of milestones, mitochondrial dysfunction, and episodic rigidity in a 46:XY male with a de novo MECP2 gene mutation. J Child Neurol 2010; 25(5): 633-6.
49. Knerr I, Gibson KM, Jakobs C, Pearl PL. Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients. CNS Spectr 2008; 13(7): 598-605.
50. Kim KJ, Pearl PL, Jensen K, et al. Succinic semialdehyde dehydrogenase: biochemical-molecular-clinical disease mechanisms, redox regulation, and functional significance. Antioxid Redox Signal 2011; 15(3): 691-718.
51. Frye RE. 15q11.2-13 duplication, mitochondrial dysfunction, and developmental disorders. J Child Neurol 2009; 24(10): 1316-20.
52. Filipek PA, Juranek J, Smith M, et al. Mitochondrial dysfunction in autistic patients with 15q inverted duplication. Ann Neurol 2003; 53(6): 801-4.
53. Pagano G, Castello G. Oxidative stress and mitochondrial dysfunction in Down syndrome. Adv Exp Med Biol 2012; 724: 291-9.
54. Pallardo FV, Lloret A, Lebel M, et al. Mitochondrial dysfunction in some oxidative stress-related genetic diseases: Ataxia-Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome. Biogerontology 2010; 11(4): 401-19.
55. Frye RE. Mitochondrial disease in 22q13 duplication syndrome. J Child Neurol 2012; 27(7): 942-9.
56. Su H, Fan W, Coskun PE, et al. Mitochondrial dysfunction in CA1 hippocampal neurons of the UBE3A deficient mouse model for Angelman syndrome. Neurosci Lett 2011; 487(2): 129-33.
57. Hertz-Picciotto I, Delwiche L. The rise in autism and the role of age at diagnosis. Epidemiology 2009; 20(1): 84-90.
58. Marazziti D, Baroni S, Picchetti M, et al. Mitochondrial alterations and neuropsychiatric disorders. Curr Med Chem 2011; 18(30): 4715-21.
59. Alvarez-Iglesias V, Mosquera-Miguel A, Cusco I, Carracedo A, Perez-Jurado LA, Salas A. Reassessing the role of mitochondrial DNA mutations in autism spectrum disorder. BMC Med Genet 2011; 12: 50.
60. Persico AM, Napolioni V. Autism genetics. Behav Brain Res 2013; 251: 95-112.
61. Hadjixenofontos A, Schmidt MA, Whitehead PL, et al. Evaluating mitochondrial DNA variation in autism spectrum disorders. Ann Hum Genet 2013; 77(1): 9-21.
62. Herbert MR, Russo JP, Yang S, et al. Autism and environmental genomics. Neurotoxicology 2006; 27(5): 671-84.
63. Ashwood P, Van de Water J. Is autism an autoimmune disease? Autoimmun Rev 2004; 3(7-8): 557-62.
64. Bayona-Bafaluy MP, Lopez-Gallardo E, Montoya J, Ruiz-Pesini E. Maternally inherited susceptibility to cancer. Biochim Biophys Acta 2011; 1807(6): 643-9.
65. Nishigaki Y, Fuku N, Tanaka M. Mitochondrial haplogroups associated with lifestyle-related diseases and longevity in the Japanese population. Geriatr Gerontol Int 2010; 10(Suppl 1): S221-35.
66. Schmidt RJ, Tancredi DJ, Ozonoff S, et al. Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (CHildhood Autism Risks from Genetics and Environment) case-control study. Am J Clin Nutr 2012; 96(1): 80-9.
67. Lyall K, Schmidt RJ, Hertz-Picciotto I. Maternal lifestyle and environmental risk factors for autism spectrum disorders. Int J Epidemiol 2014; 43(2): 443-64.
68. Schmidt RJ, Tancredi DJ, Krakowiak P, Hansen RL, Ozonoff S. Maternal intake of supplemental iron and risk of autism spectrum disorder. Am J Epidemiol 2014; 180(9): 890-900.
69. Harvey L, Boksa P. Additive effects of maternal iron deficiency and prenatal immune activation on adult behaviors in rat offspring. Brain Behav Immun 2014; 40: 27-37.
70. Nuttall JR. The plausibility of maternal toxicant exposure and nutritional status as contributing factors to the risk of autism spectrum disorders. Nutr Neurosci 2015; [Epub ahead of print].
71. Fowler BA, Woods JS. Ultrastructural and biochemical changes in renal mitochondria during chronic oral methyl mercury exposure: the relationship to renal function. Exp Mol Pathol 1977; 27(3): 403-12.
72. Shenker BJ, Guo TL, Insung O, Shapiro IM. Induction of apoptosis in human T-cells by methyl mercury: temporal relationship between mitochondrial dysfunction and loss of reductive reserve. Toxicol Appl Pharmacol 1999; 157(1): 23-35.
73. Pourahmad J, Mihajlovic A, O'Brien PJ. Hepatocyte lysis induced by environmental metal toxins may involve apoptotic death signals initiated by mitochondrial injury. Adv Exp Med Biol 2001; 500: 249-52.
74. Goyer RA. Toxic and essential metal interactions. Annu Rev Nutr 1997; 17: 37-50.
75. Hiura TS, Li N, Kaplan R, Horwitz M, Seagrave JC, Nel AE. The role of a mitochondrial pathway in the induction of apoptosis by chemicals extracted from diesel exhaust particles. J Immunol 2000; 165(5): 2703-11.
76. Wong PW, Garcia EF, Pessah IN. ortho-substituted PCB95 alters intracellular calcium signaling and causes cellular acidification in PC12 cells by an immunophilin-dependent mechanism. J Neurochem 2001; 76(2): 450-63.
77. Volk HE, Hertz-Picciotto I, Delwiche L, Lurmann F, McConnell R. Residential proximity to freeways and autism in the CHARGE study. Environ Health Perspect 2011; 119(6): 873-7.
78. Volk HE, Lurmann F, Penfold B, Hertz-Picciotto I, McConnell R. Traffic-related air pollution, particulate matter, and autism. JAMA Psychiatry 2013; 70(1): 71-7.
79. Volk HE, Kerin T, Lurmann F, Hertz-Picciotto I, McConnell R, Campbell DB. Autism spectrum disorder: interaction of air pollution with the MET receptor tyrosine kinase gene. Epidemiology 2014; 25(1): 44-7.
80. Sherer TB, Richardson JR, Testa CM, et al. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem 2007; 100(6): 1469-79.
81. Yamano T, Morita S. Effects of pesticides on isolated rat hepatocytes, mitochondria, and microsomes II. Arch Environ Contam Toxicol 1995; 28(1): 1-7.
82. Patterson PH. Maternal infection and immune involvement in autism. Trends Mol Med 2011; 17(7): 389-94.
83. Atladottir HO, Henriksen TB, Schendel DE, Parner ET. Autism after infection, febrile episodes, and antibiotic use during pregnancy: an exploratory study. Pediatrics 2012; 130(6): e1447-54.
84. Knuesel I, Chicha L, Britschgi M, et al. Maternal immune activation and abnormal brain development across CNS disorders. Nat Rev Neurol 2014; 10(11): 643-60.
85. Poletaev AB, Poletaeva AA, Pukhalenko AI, Zamaleeva RS, Cherepanova NA, Frizin DV. Adaptive maternal immune deviations as a ground for autism spectrum disorders development in children. Folia Med 2014; 56(2): 73-80.
86. Onore CE, Schwartzer JJ, Careaga M, Berman RF, Ashwood P. Maternal immune activation leads to activated inflammatory macrophages in offspring. Brain Behav Immun 2014; 38: 220-6.
87. Mazina V, Gerdts J, Trinh S, et al. Epigenetics of autism-related impairment: copy number variation and maternal infection. J Dev Behav Pediatr 2015; 36(2): 61-7.
88. Lee BK, Magnusson C, Gardner RM, et al. Maternal hospitalization with infection during pregnancy and risk of autism spectrum disorders. Brain Behav Immun 2015; 44: 100-5.
89. Zerbo O, Qian Y, Yoshida C, Grether JK, Van de Water J, Croen LA. Maternal Infection During Pregnancy and Autism Spectrum Disorders. J Autism Dev Disord 2015; 45(12): 4015-25.
90. Anonymous. Possible link between the contactin 4 gene and autism spectrum disorder identified. Fut Neurol 2008; 3(3): 225-7.
91. Buxbaum JD, Silverman J, Keddache M, et al. Linkage analysis for autism in a subset families with obsessive-compulsive behaviors: evidence for an autism susceptibility gene on chromosome 1 and further support for susceptibility genes on chromosome 6 and 19. Mol Psychiatry 2004; 9(2): 144-50.
92. Feuk L. Copy number variation in the autism genome. Expert Opin Med Diagn 2008; 2(4): 417-28.
93. Kim SJ, Cox N, Courchesne R, et al. Transmission disequilibrium mapping at the serotonin transporter gene (SLC6A4) region in autistic disorder. Mol Psychiatry 2002; 7(3): 278-88.
94. Li H, Yamagata T, Mori M, Momoi MY. Absence of causative mutations and presence of autism-related allele in FOXP2 in Japanese autistic patients. Brain Dev 2005; 27(3): 207-10.
95. Nagarajan RP, Patzel KA, Martin M, et al. MECP2 promoter methylation and X chromosome inactivation in autism. Autism Res 2008; 1(3): 169-78.
96. Petit E, Herault J, Raynaud M, et al. X chromosome and infantile autism. Biol Psychiatry 1996; 40(6): 457-64.
97. Ramanathan S, Woodroffe A, Flodman PL, et al. A case of autism with an interstitial deletion on 4q leading to hemizygosity for genes encoding for glutamine and glycine neurotransmitter receptor subunits (AMPA 2: GLRA3: GLRB) and neuropeptide receptors NPY1R, NPY5R. BMC Med Genet 2004; 5: 10.
98. Ramoz N, Reichert JG, Smith CJ, et al. Linkage and association of the mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism. Am J Psychiatry 2004; 161(4): 662-9.
99. Chao HT, Chen H, Samaco RC, et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 2010; 468(7321): 263-9.
100. Belmonte MK, Bourgeron T. Fragile X syndrome and autism at the intersection of genetic and neural networks. Nat Neurosci 2006; 9(10): 1221-5.
101. Zecavati N, Spence SJ. Neurometabolic disorders and dysfunction in autism spectrum disorders. Curr Neurol Neurosci Rep 2009; 9(2): 129-36.
102. Frustaci A, Neri M, Cesario A, et al. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radic Biol Med 2012; 52(10): 2128-41.
103. Obrenovich ME, Shamberger RJ, Lonsdale D. Altered heavy metals and transketolase found in autistic spectrum disorder. Biol Trace Elem Res 2011; 144(1-3): 475-86.
104. Ming X, Johnson WG, Stenroos ES, Mars A, Lambert GH, Buyske S. Genetic variant of glutathione peroxidase 1 in autism. Brain Dev 2010; 32(2): 105-9.
105. James SJ, Rose S, Melnyk S, et al. Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. Faseb J 2009; 23(8): 2374-83.
106. Palmieri L, Persico AM. Mitochondrial dysfunction in autism spectrum disorders: cause or effect? Biochim Biophys Acta 2010; 1797(6-7): 1130-7.
107. Clark-Taylor T, Clark-Taylor BE. Is autism a disorder of fatty acid metabolism? Possible dysfunction of mitochondrial beta-oxidation by long chain acyl-CoA dehydrogenase. Med Hypotheses 2004; 62(6): 970-5.
108. Fillano JJ, Goldenthal MJ, Rhodes CH, Marin-Garcia J. Mitochondrial dysfunction in patients with hypotonia, epilepsy, autism, and developmental delay: HEADD syndrome. J Child Neurol 2002; 17(6): 435-9.
109. Lombard J. Autism: a mitochondrial disorder? Med Hypotheses 1998; 50(6): 497-500.
110. McDonald TA. A perspective on the potential health risks of PBDEs. Chemosphere 2002; 46(5): 745-55.
111. Sjodin A, Patterson DG Jr, Bergman A. A review on human exposure to brominated flame retardants--particularly polybrominated diphenyl ethers. Environ Int 2003; 29(6): 829-39.
112. De Wit CA. An overview of brominated flame retardants in the environment. Chemosphere 2002; 46(5): 583-624.
113. Gundersen HJ, Jensen EB, Kieu K, Nielsen J. The efficiency of systematic sampling in stereology--reconsidered. J Microsc 1999; 193(Pt 3): 199-211.
114. Darnerud PO. Toxic effects of brominated flame retardants in man and in wildlife. Environ Int 2003; 29(6): 841-53.
115. Park HY, Hertz-Picciotto I, Sovcikova E, Kocan A, Drobna B, Trnovec T. Neurodevelopmental toxicity of prenatal polychlorinated biphenyls (PCBs) by chemical structure and activity: a birth cohort study. Environ Health 2010; 9: 51.
116. Schwarzenbach RP, Escher BI, Fenner K, et al. The challenge of micropollutants in aquatic systems. Science 2006; 313(5790): 1072-7.
117. Wang Y, Zhao C, Ma W, Liu H, Wang T, Jiang G. Quantitative structure-activity relationship for prediction of the toxicity of polybrominated diphenyl ether (PBDE) congeners. Chemosphere 2006; 64(4): 515-24.
118. Noren K, Meironyte D. Certain organochlorine and organobromine contaminants in Swedish human milk in perspective of past 20-30 years. Chemosphere 2000; 40(9-11): 1111-23.
119. Hale RC, Alaee M, Manchester-Neesvig JB, Stapleton HM, Ikonomou MG. Polybrominated diphenyl ether flame retardants in the North American environment. Environ Int 2003; 29(6): 771-9.
120. Bakker MI, De Winter-Sorkina R, De Mul A, Boon PE, Van Donkersgoed G, Van Klaveren JD, et al. Dietary intake of polybrominated diphenylethers in the Netherlands. Organohalogen Compd 2006; 68: 387-90.
121. Bocio A, Domingo JL, Marti-Cid R, Mata E, Teixido A, Llobet JM. Dietary intake of PBDEs by the population of Catalonia, Spain. Temporal trend. Organohalogen Compd 2007; 69: 327.
122. Bocio A, Llobet JM, Domingo JL, Corbella J, Teixido A, Casas C. Polybrominated Diphenyl Ethers (PBDEs) in Foodstuffs: Human Exposure through the Diet. J Agric Food Chem 2003; 51(10): 3191-5.
123. Dirtu AC, Covaci A. Daily intake of OCPs, PCBs and PBDEs from food consumption and indoor dust ingestion in Romania. Organohalogen Compd 2008; 70: 562-5.
124. Dirtu AC, Covaci A. Estimation of Daily Intake of Organohalogenated Contaminants from Food Consumption and Indoor Dust Ingestion in Romania. Environ Sci Technol 2010; 44(16): 6297-304.
125. Fernandes A, White S, D'Silva K, Rose M. Simultaneous determination of PCDDs, PCDFs, PCBs and PBDEs in food. Talanta 2004; 63(5): 1147-55.
126. Gensler M, Schwind KH, Jira W. Polybrominated diphenylether (PBDE) in animal food. Fleischwirtschaft 2009; 89(5): 105-10.
127. Huwe JK, Larsen GL. Polychlorinated Dioxins, Furans, and Biphenyls, and Polybrominated Diphenyl Ethers in a U.S. Meat Market Basket and Estimates of Dietary Intake. Environ Sci Technol 2005; 39(15): 5606-11.
128. Kim M, Kim DG, Choi SW, Bong YH, Jang JH, Chung GS. Levels and dietary intakes of polybrominated diphenyl ethers and hexachlorobenzene in meat in Korea. Organohalogen Compd 2008; 70: 1780-3.
129. Kiviranta H, Hallikainen A, Ruokojarvi P, Rantakokko P, Vartiainen T. PCDD/F, PCB, and PBDE levels in finnish foodstuffs in 2003-2005. Organohalogen Compd 2006; 68: 1898-901.
130. Ohta S, Ishizuka D, Nishimura H, et al. Comparison of polybrominated diphenyl ethers in fish, vegetables, and meats and levels in human milk of nursing women in Japan. Chemosphere 2002; 46(5): 689-96.
131. Schecter A, Paepke O, Ryan JJ, et al. PBDEs in U.S. milk, blood, and food, and temporal trends for PBDEs, PCDDs, and PCBs in US blood. Organohalogen Compd 2004; 66: 2800-6.
132. Schecter A, Paepke O, Tung, K.-C.; Staskal D, Birnbaum L. Polybrominated Diphenyl Ethers Contamination of United States Food. Environ Sci Technol 2004; 38(20): 5306-11.
133. Seo J, Lee, NH, Shin JH, et al. Dietary PBDE intake: a marketbasket study in Korea. Organohalogen Compd 2008; 70: 2147-50.
134. Shen HT, Han JL, Ren YP. Preliminary evaluation of PCDD-Fs in agricultural products and human intake. Huanjing Huaxue 2007; 26(2): 269-70.
135. Sun SJ, Zhao JH, Leng JH, et al. Levels of dioxins and polybrominated diphenyl ethers in human milk from three regions of northern China and potential dietary risk factors. Chemosphere 2010; 80(10): 1151-9.
136. Tlustos C, Fernandes A, White S, Rose M. PBDEs, PBDD/Fs and PBBs in carcass fat, liver, eggs and milk produced in Ireland. Organohalogen Compd 2008; 70: 209-12.
137. Yu YX, Li JL, Zhang XY, et al. Assessment of the Bioaccessibility of Polybrominated Diphenyl Ethers in Foods and the Correlations of the Bioaccessibility with Nutrient Contents. J Agric Food Chem 2010; 58(1): 301-8.
138. Hites RA, Foran JA, Schwager SJ, Knuth BA, Hamilton MC, Carpenter DO. Global assessment of polybrominated diphenyl ethers in farmed and wild salmon. Environ Sci Technol 2004; 38(19): 4945-9.
139. Perello G, Marti-Cid R, Castell V, Llobet JM, Domingo JL. Concentrations of polybrominated diphenyl ethers, hexachlorobenzene and polycyclic aromatic hydrocarbons in various foodstuffs before and after cooking. Food Chem Toxicol 2009; 47(4): 709-15.
140. Sjodin A, Hagmar L, Klasson-Wehler E, Kronholm-Dlab K, Jakobsson E, Bergman O. Flame retardant exposure: Polybrominated diphenyl ethers in blood from Swedish workers. Environ Health Perspect 1999; 107(8): 643-8.
141. Lind Y, Darnerud PO, Atuma S, et al. Polybrominated diphenyl ethers in breast milk from Uppsala County, Sweden. Environ Res 2003; 93(2): 186-94.
142. Schecter A, Pavuk M, Paepke O, Ryan JJ, Birnbaum L, Rosen R. Polybrominated diphenyl ethers (PBDEs) in U.S. mothers' milk. Environ Health Perspect 2003; 111(14): 1723-9.
143. Betts KS. Rapidly rising PBDE levels in North America. Environ Sci Technol 2002; 36(3): 50A-2A.
144. She J, Petreas M, Winkler J, Visita P, McKinney M, Kopec D. PBDEs in the San Francisco Bay Area: measurements in harbor seal blubber and human breast adipose tissue. Chemosphere 2002; 46(5): 697-707.
145. Petreas M, Nelson D, Brown FR, Goldberg D, Hurley S, Reynolds P. High concentrations of polybrominated diphenylethers (PBDEs) in breast adipose tissue of California women. Environ Int 2011; 37(1): 190-7.
146. Davis JA, Hetzel F, Oram JJ, McKee LJ. Polychlorinated biphenyls (PCBs) in San Francisco Bay. Environ Res 2007; 105(1): 67-86.
147. Flegal AR, Brown CL, Squire S, Ross JR, Scelfo GM, Hibdon S. Spatial and temporal variations in silver contamination and toxicity in San Francisco Bay. Environ Res 2007; 105(1): 34-52.
148. Luengen AC, Friedman CS, Raimondi PT, Flegal AR. Evaluation of mussel immune responses as indicators of contamination in San Francisco Bay. Mar Environ Res 2004; 57(3): 197-212.
149. Oros DR, Ross JR, Spies RB, Mumley T. Polycyclic aromatic hydrocarbon (PAH) contamination in San Francisco Bay: a 10-year retrospective of monitoring in an urbanized estuary. Environ Res 2007; 105(1): 101-18.
150. Petreas M, She J, Brown FR, et al. High body burdens of 2:2',4:4'-tetrabromodiphenyl ether (BDE-47) in California women. Environ Health Perspect 2003; 111(9): 1175-9.
151. Rose M, Bennett DH, Bergman A, Fangstrom B, Pessah IN, Hertz-Picciotto I. PBDEs in 2-5 year-old children from California and associations with diet and indoor environment. Environ Sci Technol 2010; 44(7): 2648-53.
152. Toms LM, Harden F, Paepke O, Hobson P, Ryan JJ, Mueller JF. Higher accumulation of polybrominated diphenyl ethers in infants than in adults. Environ Sci Technol 2008; 42(19): 7510-5.
153. Affairs DoC. Bureau of Home Furnishings and Thermal Insulation. North Highlands, CA, USA, 1992.
154. Alexander FE, Patheal SL, Biondi A, et al. Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res 2001; 61(6): 2542-6.
155. Ma X, Buffler PA, Gunier RB, et al. Critical windows of exposure to household pesticides and risk of childhood leukemia. Environ Health Perspect 2002; 110(9): 955-60.
156. Woodruff TJ, Axelrad DA, Kyle AD, Nweke O, Miller GG, Hurley BJ. Trends in environmentally related childhood illnesses. Pediatrics 2004; 113(4 II): 1133-40.
157. Mazdai A, Dodder NG, Abernathy MP, Hites RA, Bigsby RM. Polybrominated diphenyl ethers in maternal and fetal blood samples. Environ Health Perspect 2003; 111(9): 1249-52.
158. Zhou T, Ross DG, DeVito MJ, Crofton KM. Effects of short-term in vivo exposure to polybrominated diphenyl ethers on thyroid hormones and hepatic enzyme activities in weanling rats. Toxicol Sci 2001; 61(1): 76-82.
159. Eriksson P, Jakobsson E, Fredriksson A. Brominated flame retardants: A novel class of developmental neurotoxicants in our environment? Environ Health Perspect 2001; 109(9): 903-8.
160. Gill U, Chu I, Ryan JJ, Feeley M. Polybrominated diphenyl ethers: human tissue levels and toxicology. Rev Environ Contam Toxicol 2004; 183: 55-97.
161. Kim KH, Bose DD, Ghogha A, et al. Para-and ortho-substitutions are key determinants of polybrominated diphenyl ether activity toward ryanodine receptors and neurotoxicity. Environ Health Perspect 2011; 119(4): 519-26.
162. Pessah IN, Cherednichenko G, Lein PJ. Minding the calcium store: Ryanodine receptor activation as a convergent mechanism of PCB toxicity. Pharmacol Ther 2010; 125(2): 260-85.
163. Miller MF, Chernyak SM, Batterman S, Loch-Caruso R. Polybrominated diphenyl ethers in human gestational membranes from women in southeast Michigan. Environ Sci Technol 2009; 43(9): 3042-6.
164. Mariottini M, Corsi I, Della Torre C, et al. Biomonitoring of polybrominated diphenyl ether (PBDE) pollution: a field study. Comp Biochem Physiol C Toxicol Pharmacol 2008; 148(1): 80-6.
165. Roosens L, Dirtu AC, Goemans G, et al. Brominated flame retardants and polychlorinated biphenyls in fish from the river Scheldt, Belgium. Environ Int 2008; 34(7): 976-83.
166. Manchester-Neesvig JB, Valters K, Sonzogni WC. Comparison of polybrominated diphenyl ethers (PBDEs) and polychlorinated biphenyls (PCBs) in Lake Michigan salmonids. Environ Sci Technol 2001; 35(6): 1072-7.
167. Birnbaum LS, Staskal DF. Brominated flame retardants: Cause for concern? Environ Health Perspect 2004; 112(1): 9-17.
168. Meerts IATM, van Zanden JJ, Luijks EAC, et al. Potent competitive interactions of some brominated flame retardants and related compounds with human transthyretin in vitro. Toxicol Sci 2000; 56(1): 95-104.
169. Zhou T, Taylor MM, DeVito MJ, Crofton KM. Developmental exposure to brominated diphenyl ethers results in thyroid hormone disruption. Toxicol Sci 2002; 66(1): 105-16.
170. Stoker TE, Laws SC, Crofton KM, Hedge JM, Ferrell JM, Cooper RL. Assessment of DE-71: a commercial polybrominated diphenyl ether (PBDE) mixture, in the EDSP male and female pubertal protocols. Toxicol Sci 2004; 78(1): 144-55.
171. Kodavanti PRS, Royland JE, Ramabhadran R, Osorio C, Alzate O. Changes in proteomic profiles of cerebellum following developmental exposure to aroclor 1254 or DE-71. Organohalogen Compd 2007; 69: 494.
172. van Boxtel AL, Kamstra JH, Cenijn PH, et al. Microarray Analysis Reveals a Mechanism of Phenolic Polybrominated Diphenylether Toxicity in Zebrafish. Environ Sci Technol 2008; 42(5): 1773-9.
173. Tseng LH, Lee CW, Pan MH, et al. Postnatal exposure of the male mouse to 2:2',3:3',4:4',5:5',6:6'-decabrominated diphenyl ether: Decreased epididymal sperm functions without alterations in DNA content and histology in testis. Toxicology 2006; 224(1-2): 33-43.
174. Talsness CE, Shakibaei M, Kuriyama SN, et al. Ultrastructural changes observed in rat ovaries following in utero and lactational exposure to low doses of a polybrominated flame retardant. Toxicol Lett 2005; 157(3): 189-202.
175. Nie F, Qu J, Yang G, Wu W. Oxidative damage of decabromodiphenyl ether to the mitochondria from the liver of Carassius auratus in vitro. Anquan Yu Huanjing Xuebao 2008; 8(5): 5-8.
176. Hsu PC, Tseng LH, Lee CW. Effects of prenatal exposure of decabrominated diphenyl ether (PCBDE 209) on reproductive system in male mice. Organohalogen Compd 2006; 68: 1547-50.
177. Talsness CE, Shakibaei M, Kuriyama S, de Souza C, Chahoud I. Ultrastructural changes in the ovaries of adult offspring following a single maternal exposure to low dose 2:2',4:4',5-pentabromodiphenyl ether. Organohalogen Compound 2003; 61: 88-91.
178. Blaylock RL. A possible central mechanism in autism spectrum disorders, part 2: immunoexcitotoxicity. Altern Ther Health Med 2009; 15(1): 60-7.
179. Lerman-Sagie T, Leshinsky-Silver E, Watemberg N, Lev D. Should autistic children be evaluated for mitochondrial disorders? J Child Neurol 2004; 19(5): 379-81.
180. Hertz-Picciotto I, Bergman A, Fangstrom B, et al. Polybrominated diphenyl ethers in relation to autism and developmental delay: A case-control study. Environ Health 2011; 10(1): 1.
181. Valdameri G, Trombetta-Lima M, Worfel PR, et al. Involvement of catalase in the apoptotic mechanism induced by apigenin in HepG2 human hepatoma cells. Chem Biol Interact 2011; 193(2): 180-9.
182. Chang YF, Hsu YC, Hung HF, et al. Quercetin induces oxidative stress and potentiates the apoptotic action of 2-methoxyestradiol in human hepatoma cells. Nutr Cancer 2009; 61(5): 735-45.
183. Lima CF, Valentao PC, Andrade PB, Seabra RM, Fernandes-Ferreira M, Pereira-Wilson C. Water and methanolic extracts of Salvia officinalis protect HepG2 cells from t-BHP induced oxidative damage. Chem Biol Interact 2007; 167(2): 107-15.
184. Garcia-Alonso J, Ros G, Jesus Periago M. Antiproliferative and cytoprotective activities of a phenolic-rich juice in HepG2 cells. Food Res Int 2006; 39(9): 982-91.
185. Alia M, Ramos S, Mateos R, Granado-Serrano AB, Bravo L, Goya L. Quercetin protects human hepatoma HepG2 against oxidative stress induced by tert-butyl hydroperoxide. Toxicol Appl Pharmacol 2006; 212(2): 110-8.
186. Masella R, Di Benedetto R, Vari R, Filesi C, Giovannini C. Novel mechanisms of natural antioxidant compounds in biological systems: involvement of glutathione and glutathione-related enzymes. J Nutr Biochem 2005; 16(10): 577-86.
187. Andreadi CK, Howells LM, Atherfold PA, Manson MM. Involvement of Nrf2: p38: B-Raf, and nuclear factor-κB, but not phosphatidylinositol 3-kinase, in induction of hemeoxygenase-1 by dietary polyphenols. Mol Pharmacol 2006; 69(3): 1033-40.
188. Ding M, Zhao J, Bowman L, Lu Y, Shi X. Inhibition of AP-1 and MAPK signaling and activation of Nrf2/ARE pathway by quercitrin. Int J Oncol 2010; 36(1): 59-67.
189. Tanigawa S, Fujii M, Hou DX. Action of Nrf2 and Keap1 in AREmediated NQO1 expression by quercetin. Free Radic Biol Med 2007; 42(11): 1690-703.
190. Andreadi CK, Howells LM, Atherfold PA, Manson MM. Involvement of Nrf2: p38: B-Raf, and nuclear factor-kappaB, but not phosphatidylinositol 3-kinase, in induction of hemeoxygenase-1 by dietary polyphenols. Mol Pharmacol 2006; 69(3): 1033-40.
191. Eggler AL, Gay KA, Mesecar AD. Molecular mechanisms of natural products in chemoprevention: induction of cytoprotective enzymes by Nrf2. Mol Nutr Food Res 2008; 52(Suppl 1): S84-94.
192. Nebreda AR, Porras A. p38 MAP kinases: beyond the stress response. Trends Biochem Sci 2000; 25(6): 257-60.
193. Wang X, Ye XL, Liu R, et al. Antioxidant activities of oleanolic acid in vitro: possible role of Nrf2 and MAP kinases. Chem Biol Interact 2010; 184(3): 328-37.
194. Pi J, Bai Y, Reece JM, et al. Molecular mechanism of human Nrf2 activation and degradation: role of sequential phosphorylation by protein kinase CK2. Free Radic Biol Med 2007; 42(12): 1797-806.
195. Copple IM, Goldring CE, Jenkins RE, et al. The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system. Hepatology 2008; 48(4): 1292-301.
196. Goldring CE, Kitteringham NR, Elsby R, et al. Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice. Hepatology 2004; 39(5): 1267-76.
197. Naidu S, Vijayan V, Santoso S, Kietzmann T, Immenschuh S. Inhibition and genetic deficiency of p38 MAPK up-regulates heme oxygenase-1 gene expression via Nrf2. J Immunol 2009; 182(11): 7048-57.
198. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta 2006; 1757(5-6): 509-17.
199. Szeto HH. Mitochondria-targeted peptide antioxidants: Novel neuroprotective agents. AAPS Journal 2006; 8(3): 521-31.
200. Lee JM, Shih AY, Murphy TH, Johnson JA. NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem 2003; 278(39): 37948-56.
201. Napoli E, Wong S, Hertz-Picciotto I, Giulivi C. Deficits in bioenergetics and impaired immune response in granulocytes from children with autism. Pediatrics 2014; 133(5): e1405-10.
202. Linnane AW, Ozawa T, Marzuki S, Tanaka M. Mitochondrial-DNA Mutations as an Important Contributor to Ageing and Degenerative Diseases. Lancet 1989; 1(8639): 642-5.
203. Lee HC, Pang CY, Hsu HS, Wei YH. Differential accumulations of 4:977 bp deletion in mitochondrial DNA of various tissues in human ageing. Biochim Biophys Acta 1994; 1226(1): 37-43.
204. Fukui H, Moraes CT. Mechanisms of formation and accumulation of mitochondrial DNA deletions in aging neurons. Hum Mol Genet 2009; 18(6): 1028-36.
205. Lee HC, Yin PH, Lu CY, Chi CW, Wei YH. Increase of mitochondria and mitochondrial DNA in response to oxidative stress in human cells. Biochem J 2000; 348 Pt 2: 425-32.
206. Chou YF, Huang RF. Mitochondrial DNA deletions of blood lymphocytes as genetic markers of low folate-related mitochondrial genotoxicity in peripheral tissues. Eur J Nutr 2009; 48(7): 429-36.
207. Yeargin-Allsopp M, Rice C, Karapurkar T, Doernberg N, Boyle C, Murphy C. Prevalence of autism in a US metropolitan area. JAMA 2003; 289(1): 49-55.
208. Lee HC, Lu CY, Fahn HJ, Wei YH. Aging-and smokingassociated alteration in the relative content of mitochondrial DNA in human lung. FEBS Lett 1998; 441(2): 292-6.
209. Moreno-Loshuertos R, Acin-Perez R, Fernandez-Silva P, et al. Differences in reactive oxygen species production explain the phenotypes associated with common mouse mitochondrial DNA variants. Nat Genet 2006; 38(11): 1261-8.
210. Ylikallio E, Tyynismaa H, Tsutsui H, Ide T, Suomalainen A. High mitochondrial DNA copy number has detrimental effects in mice. Hum Mol Genet 2010; 19(13): 2695-705.
211. Rose S, Melnyk S, Pavliv O, et al. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. Transl Psychiatry 2012; 2: e134.
212. James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 2006; 141b(8): 947-56.
213. Melnyk S, Fuchs GJ, Schulz E, et al. Metabolic imbalance associated with methylation dysregulation and oxidative damage in children with autism. J Autism Dev Disord 2012; 42(3): 367-77.
214. Finkelstein JD. Metabolic regulatory properties of Sadenosylmethionine and S-adenosylhomocysteine. Clin Chem Lab Med 2007; 45(12): 1694-9.
215. Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern Med Rev 2008; 13(3): 216-26.
216. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, Wallace DC. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet 1992; 2(4): 324-9.
217. Yadava N, Nicholls DG. Spare respiratory capacity rather than oxidative stress regulates glutamate excitotoxicity after partial respiratory inhibition of mitochondrial complex I with rotenone. J Neurosci 2007; 27(27): 7310-7.
218. Noch E, Khalili K. Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity. Cancer Biol Ther 2009; 8(19): 1791-7.
219. Kraft AD, Harry GJ. Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Environ Res Public Health 2011; 8(7): 2980-3018.
220. Ashwood P, Enstrom A, Krakowiak P, et al. Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol 2008; 204(1-2): 149-53.
221. Frye RE, Delatorre R, Taylor H, et al. Redox metabolism abnormalities in autistic children associated with mitochondrial disease. Transl Psychiatry 2013; 3: e273.
222. Napoli E, Duenas N, Giulivi C. Potential therapeutic use of the ketogenic diet in autistic spectrum disorders. Front Pediatr 2014; 2014: 2.
223. Gargus JJ. Mitochondrial energy-deficiency endophenotypes in autism. J Neurochem 2008; 104: 16.
224. Huang J, Lam GY, Brumell JH. Autophagy signaling through reactive oxygen species. Antioxid Redox Signal 2011; 14(11): 2215-31.
225. Poyton RO, Ball KA, Castello PR. Mitochondrial generation of free radicals and hypoxic signaling. Trends Endocrinol Metab 2009; 20(7): 332-40.
226. Luckhart S, Pakpour N, Giulivi C. Host-pathogen interactions in malaria: cross-kingdom signaling and mitochondrial regulation. Curr Opin Immunol 2015; 36: 73-9.